Icatibant
Firazyr
A synthetic decapeptide bradykinin B2 receptor antagonist. Approved in the US for acute attacks of hereditary angioedema (HAE) in adults.
- Half-life
- 1.4 h
- Out of system
- ~7 h
- Route
- Subcutaneous
- Level
- —
Class (Bradykinin B2 receptor antagonist), half-life and route from the FDA label: Firazyr (icatibant) injection (U.S. National Library of Medicine, DailyMed), checked 2026-09-26.
What Icatibant is used for
- Treatment of acute attacks of hereditary angioedema in adults 18 and older (FDA label)
How it's typically used
Prescription medicine in the US, injected when an attack starts. The prescriber sets the dose and limits; the FDA label is cited on this page.
What to watch for
- A laryngeal attack can block the airway: seek emergency care as well as injecting
- Injection-site reactions occur in most patients (97% in clinical trials)
Common questions
- What is the half-life of Icatibant?
- Icatibant has an approximate elimination half-life of 1.4 h.
- How long does Icatibant stay in your system?
- Roughly 97% of a dose has cleared after five half-lives — about ~7 h for Icatibant. That is the window that matters for washouts, bloodwork and surgery.
- How is Icatibant taken?
- Icatibant is typically administered by the subcutaneous route. Prescription medicine in the US, injected when an attack starts. The prescriber sets the dose and limits; the FDA label is cited on this page.
- What are the risks of Icatibant?
- A laryngeal attack can block the airway: seek emergency care as well as injecting Injection-site reactions occur in most patients (97% in clinical trials)
About Other research compounds
- What they are
- Nootropics, metabolic agents, and research compounds that don't fit the other classes.
- How they're run
- Route and schedule vary widely — check the individual entry.
- What to watch
- This is the least-characterised corner of the atlas. Read the full guide, and treat anything without published human data as exactly that.
Other other research compounds
Peptid AI is an educational and self-tracking tool — not a medical service, and not a vendor. Nothing here is medical advice, a prescription, or an endorsement. Doses reflect what is commonly reported in research literature; they are not recommendations. Many compounds listed are experimental, not approved for human use, and/or controlled substances that are illegal to possess without a prescription in many countries. Always consult a qualified physician before starting, changing, or stopping any protocol.